MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Impact · against what's priced in

The collaboration between MiniMed and Abbott to integrate dual glucose-ketone sensors introduces a high-value clinical capability to prevent DKA, potentially increasing market share and pricing power. However, the immediate financial impact is limited as the technology lacks FDA clearance for the US market.

MMED+0.50

No priced-in read yet